• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

This product is currently not available for purchase.



  • ID: 1896618
  • January 2010
  • 200 Pages
  • VDM Publishing House

Neuroendocrine derangements after traumatic brain injury (TBI) have received increasing recognition in recent years. Marked changes of the hypothalamo-pituitary axis have been documented in the acute phase of TBI with as many as 80% of patients showing evidence of gonadotropin deficiency, 18% of growth hormone deficiency, 16% of corticotrophin deficiency and 40% of patients demonstrating vasopressin abnormalities. Longitudinal prospective studies have shown that some of the early abnormalities are transient, while new endocrine dysfunction becomes apparent in the post acute phase. There remains a high frequency of hypothalamic-pituitary hormone deficiencies among long term survivors of TBI with approximately 28% patients showing one or more pituitary hormone deficiencies. This is a higher frequency than previously thought and suggests that most cases of post traumatic hypopituitarism (PTHP) remain undiagnosed and untreated. The data underscore the need for the identification and appropriate timely management of hormone deficiencies, in order to optimise patient recovery from head trauma.

Note: Product cover images may vary from those shown

Amar, Agha.
Amar Agha MD FRCPI is a Consultant Pituitary Endocrinologist at Beaumont Hospital in Dublin, Ireland. Dr. Agha’s research interests include the areas of pituitary dysfunction after head trauma and radiotherapy and, glucocorticoids. He has published extensively in the leading scientific journals on these topics.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

Our Clients

Danisco A/S Eli Lilly and Company Midmark Corporation Gribbles Veterinary Pathology CEVA Santé Animale Merial Norbrook Laboratories Ltd